For Immediate Release

Rapid Dose Therapeutics Advances Cannabinoid Research and Clinical Evaluation of QuickStrip™ Platform

BURLINGTON, Ontario – February 23, 2026 – Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF), ("RDT" or the "Company"), a Canadian biotechnology company focused on innovative drug delivery solutions, today provided an update on its ongoing cannabinoid research initiatives and clinical evaluation of its proprietary QuickStrip™ oral thin film delivery platform.

Independent research led by colleagues Dr. Patrick Neary of the Faculty of Kinesiology & Health Studies at the University of Regina and Dr. Jane Alcorn of the College of Pharmacy & Nutrition at the University of Saskatchewan examines the role of naturally produced cannabinoids in pain management and neuroprotection related to concussion and participation in contact sports. This research program is supported through grant funding from the National Football League (NFL).

In parallel, a separate clinical study arm initiated in Q2 2024 is evaluating the bioavailability of cannabidiol (CBD) delivered via RDT's QuickStrip™ oral thin film compared to traditional oral dosage formats. The study is designed to assess absorption efficiency by measuring how much CBD moves through the body and how long it stays there after each type of product, we can determine whether the strips deliver CBD more efficiently than the standard oral form," said Dr. Alcorn.

The study is progressing as planned, with raw data extracted for over 60% of enrolled participants to date. Enrollment of the remaining participants is expected to continue in Q2 2026. In parallel, the real-time and accelerated stability studies of the CBD QuickStrip™ investigational product are ongoing.

The Company believes this research initiatives further validate the potential of the QuickStrip™ platform across pharmaceutical and wellness applications, particularly in areas where rapid, discreet, and efficient delivery may provide clinical and consumer advantages.

About Rapid Dose Therapeutics Corp.

Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.

Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
416-477-1052

Institutional Disclaimer

The Company does not speak on behalf of the University of Regina, the University of Saskatchewan, or the National Football League. References to independent academic research and funding sources do not constitute endorsement, sponsorship, or support of Rapid Dose Therapeutics or its technology by these institutions or organizations.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:

Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. This press release does not constitute an offer to sell or a solicitation of an offer to sell any of the securities described herein in the Common Shared States. The securities described in this news release have not been and will not be registered under the Common Shared States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the Common Shared States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.